| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7205302 | ACTELION | Heterocyclic compound derivatives and medicines |
Oct, 2026
(2 years from now) | |
| US8791122 | ACTELION | Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same |
Aug, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9173881 | ACTELION | Therapeutic compositions containing macitentan |
Aug, 2029
(5 years from now) | |
| US9284280 | ACTELION | Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Jun, 2030
(6 years from now) | |
| US10821108 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
Dec, 2036
(12 years from now) | |
| US10828298 | ACTELION | Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide |
Dec, 2036
(12 years from now) | |
Uptravi is owned by Actelion.
Uptravi contains Selexipag.
Uptravi has a total of 6 drug patents out of which 0 drug patents have expired.
Uptravi was authorised for market use on 21 December, 2015.
Uptravi is available in tablet;oral, powder;intravenous dosage forms.
Uptravi can be used as method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan, method of treating pulmonary arterial hypertension comprising administering a crystalline form of selexipag, method of treating pulmonary arterial hypertension comprising administering a tablet containing selexipag, method of treating pulmonary arterial hypertension comprising administering a solid preparation containing selexipag, method of treating pulmonary arterial hypertension comprising administering a pharmaceutical composition comprising selexipag.
Drug patent challenges can be filed against Uptravi from 22 December, 2019.
The generics of Uptravi are possible to be released after 01 December, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-106) | Dec 21, 2022 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2022 |
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2020 |
Drugs and Companies using SELEXIPAG ingredient
NCE-1 date: 22 December, 2019
Market Authorisation Date: 21 December, 2015
Treatment: Method of treating pulmonary arterial hypertension comprising administering selexipag in combination with the endothelin receptor antagonist macitentan; Method of treating pulmonary arterial hypertens...
Dosage: TABLET;ORAL; POWDER;INTRAVENOUS
UPTRAVI family patents
